Updated on 11 September 2013
With a diverse multicultural population, Australia is well placed to provide studies targeting specific demographics. The Australian government has a commitment to maintain the country's international competitiveness when it comes to clinical trials, and have recently committed $9.9 million to this cause. Also, Australia is lucky to have such an efficient regulatory system.
Current challenges relate to the research governance review process for Australian public hospital projects in a number of states, which has added to timelines and cost, despite initial intentions to speed up processes through multi-center study single ethical review system. The trouble is that this is an issue under the state's regulations, so federal money may not be able to achieve its aim here. Besides, Australia remains internationally competitive with regards to set up timelines for clinical trials. Another important part of the federal program, which is currently under way, is review of clinical trial costs. There is an aim to have more streamlined or transparent cost systems for clinical trial fees charged by investigator sites. The cost system is not to be considered a price fixing approach, but rather a basis for discussion.